Home > Party Building > Party building dynamic >

Su Dehui, Deputy Secretary of the Party Committee, Vice Chairman, and General Manager of Hunan Pharmaceutical Development Investment Group, went to the company to preach the spirit of the Third Plenary Session of the 20th Central Committee and carry out research work

Release time:2024-09-09 08:56

Source:

On the morning of September 5th, Su Dehui, Deputy Secretary of the Party Committee, Vice Chairman, and General Manager of the Group, led a team to the company to give a lecture on the spirit of the Third Plenary Session of the 20th Central Committee of the Communist Party and to conduct research work. Mo Zhong, member of the Group Party Committee and Deputy General Manager, and Chen Jianshe, Director of the Group's Quality Management Department, accompanied him. Members of the company’s leadership team, mid-level and above management personnel, as well as Party members attended the meeting.

At the meeting, Su Dehui systematically explained and deeply interpreted the themes and significant importance of the plenary session, the important speech of General Secretary Xi Jinping at the Third Plenary Session of the 20th CPC Central Committee, and, in combination with the company's actual situation, elaborated on aspects such as fully implementing the spirit of the plenary session, strengthening the determination for reform, grasping the objectives of reform, and mastering scientific methods. He delivered an excellent lecture to the company's Party members and cadres. He stressed that all Party members and cadres should deeply understand and accurately grasp the spirit of the Third Plenary Session of the 20th CPC Central Committee, and genuinely unify their thoughts and actions with its spirit, driving high-quality development of the company with a reform-oriented determination to continuously achieve new accomplishments.

Shen Fanshun gave a key report on the company's production and operation from January to August, the deepening of reform work, inspection rectification work, and the work plans and measures for the next stage. Other leadership team members and heads of relevant departments gave detailed reports on production management, drug research and development, process problem-solving, quality control, and raw material procurement.

Mo Zhong emphasized that the company should strengthen data analysis and statistics to provide a scientific and reasonable basis for development. At the same time, the focus should be on addressing production technology challenges, equipment planning, personnel training, and product sales through clear specific goals and measures, accurately accelerating the company's improvement, and ensuring achievements by the end of the year.

In his concluding remarks, Su Dehui fully affirmed the achievements made in the company’s transformation and upgrading this year. Regarding the next steps, he stated that: first, for different levels of problems at the current stage of the company, systematic thinking should be strengthened, and management planning coordinated to ensure effective results. Second, more attention should be paid to employee growth and development, with an emphasis on positive incentives, craftsmanship, and inspiring employees to treat the factory as their home with enthusiasm and creativity. Third, problems should be objectively assessed, recognized, and faced with determination and confidence, aiming to completely resolve development issues during the 14th Five-Year Plan period. Fourth, the work tasks assigned to the company should have clear completion timelines and plans, with intensive implementation efforts, anchoring annual targets to fully promote the achievement of the company's annual goals and tasks.